Could a finger prick replace blood draws for prostate cancer drug monitoring?

NCT ID NCT07344363

Recruiting now Knowledge-focused Sponsor: Centro di Riferimento Oncologico - Aviano Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing whether dried blood spots from a finger prick can reliably measure levels of common prostate cancer drugs. Researchers will compare results from the finger-prick method with standard blood tests in 100 patients. If the new method works, it could make drug monitoring easier and more convenient for patients.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: abiraterone, apalutamide, darolutamide, enzalutamide
What this could lead to: If successful, this could make it easier and less invasive to monitor drug levels in prostate cancer patients, potentially improving treatment management.
What could go wrong: This is an early-stage validation study, not a treatment trial. The new method may not prove reliable enough to replace standard blood tests.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER

Contacts and locations

Locations

Centro di Riferimento Oncologico di Aviano (CRO), IRCCS
RECRUITING

Aviano, Pordenone, 33081, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.